Candida kefyr, an uncommon but emerging fungal pathogen: Report of two cases

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1084-1088

  Corpus, Kimberly ^a   Hegeman Dingle, Rozelle ^a   Bajjoka, Iman ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Candida kefyr; Clinical course; Fungal pathogen; Treatment options

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFEPIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; ERTAPENEM; FLUCONAZOLE; ITRACONAZOLE; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN; VORICONAZOLE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PERITONITIS; CANDIDA ALBICANS; CANDIDA KEFYR; CASE REPORT; CLINICAL FEATURE; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; MALE; MYCOSIS; PATHOGENESIS; URINARY TRACT INFECTION;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; COLONIC NEOPLASMS; FEMALE; HEPATIC VEIN THROMBOSIS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 3543113109     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1084.36140     Document Type: Article

References (17)

1. Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462-78.
2. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32.
3. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
4. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in the United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
5. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7.
6. Borg-von Zepelin M, Eiffert H, Kann M, Ruchel R. Changes in the spectrum of fungal isolates: results from clinical specimens gathered in 1987/1988 compared with those in 1991/1992 in the University Hospital Gottingen, Germany. Mycoses 1993;36:247-53.
7. Arendrup M, Horn T, Frimodt-Moller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 2002;30:286-91.
8. Hodgin UG Jr. Cystitis due to Candida pseudotropicalis. Rocky Mt Med J 1969;66:30-2.
9. Morgan MA, Wilkowske CJ, Roberts GD. Candida pseudotropicalis fungemia and invasive disease in an immunocompromised patient. J Clin Microbiol 1984;20:1006-7.
10. Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses 1999;42:543-8.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed, M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
12. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from the blood. J Clin Microbiol 2003;41:78-83.
13. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001. J Clin Microbiol 2003;41:1440-6.
14. Carrillo-Munoz AJ, Tur C, Torres J. In vitro antifungal activity of sertaconazole, bifonazole, ketoconazole, and miconazole against yeasts of the Candida genus. J Antimicrob Chemother 1996;37:815-19.
15. Barchiesi F, Tortorano AM, Di Francesco LF, Cogliati M. In vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. J Antimicrob Chemother 1999;43:295-9.
16. Zer Y, Balci I, Meric G. Identification and antifungal susceptibility of Candida isolated from intensive care unit patients. Microbiologica 2002;25:489-94.
17. Arikan S, Akova M, Hayran M, et al. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis. Clin Infect Dis 1998;26:903-8.